Alkermes (ALKS) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alkermes (ALKS) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 29.4% versus a gain of 3.0%. Over five years, PAHC leads with a +75.7% price change compared with +28.2% for ALKS. Alkermes is the larger company by market cap ($6.81 billion vs $1.56 billion), about 4.4 times the size, while Phibro Animal Health is growing revenue faster (+17.1% vs -5.2%).
On valuation, Phibro Animal Health trades at a lower forward P/E (10.0x vs 22.5x for Alkermes). Phibro Animal Health pays a dividend yielding 1.25%, while Alkermes does not currently pay one. Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | PAHC |
|---|---|---|
| Share price | $40.61 | $38.30 |
| Market cap | $6.81B | $1.56B |
| 1-day change | +1.25% | +2.41% |
| YTD return | +45.14% | +2.52% |
| 1-year return | +29.41% | +3.04% |
| 5-year return | +28.23% | +75.69% |
| P/E ratio (TTM) | 106.87 | 15.76 |
| Forward P/E | 22.46 | 9.97 |
| EPS (TTM) | $0.38 | $2.43 |
| Dividend yield | 0.00% | 1.25% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $1.48B | $1.52B |
| Revenue growth (YoY) | -5.25% | +17.12% |
| Net income (latest FY) | $241.66M | $99.72M |
| Gross margin | 86.69% | 33.76% |
| Operating margin | 17.21% | 12.81% |
| Net margin | 16.37% | 6.57% |
| 52-week high | $55.67 | $60.08 |
| 52-week low | $27.00 | $28.25 |
| Distance from 52-week high | -27.05% | -36.25% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +38.59% | +14.88% |
| Average volume | 1.86M | 231.66K |
| Shares outstanding | 167.76M | 21.11M |
| Employees | 2,050 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alkermes is about 4.4 times larger than Phibro Animal Health by market value ($6.81B vs $1.56B).
- ALKS has outperformed PAHC by 26.4 percentage points over the past year.
- Alkermes trades at a higher earnings multiple (106.9x vs 15.8x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus 6.6 cents for Phibro Animal Health.
- Phibro Animal Health grew revenue faster in its latest fiscal year (+17.12% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
ALKS vs PAHC FAQ
Which is bigger, Alkermes or Phibro Animal Health?
Alkermes (ALKS) is larger, with a market capitalization of $6.81B compared with $1.56B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, ALKS or PAHC?
ALKS returned +29.41% over the past 12 months, compared with +3.04% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALKS or PAHC?
PAHC has the lower trailing P/E at 15.8, versus 106.9 for ALKS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Alkermes or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.25%, while Alkermes does not currently pay a regular dividend.
Are Alkermes and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.